- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of October 14, 2019
The Center for Biosimilars® recaps the top stories for the week of October 14, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 14, 2019.
Number 5: A pharmacists’ group has issued a global position statement in which it recommends against treating biosimilars as interchangeable.
Number 4: A new bill would amend the Affordable Care Act to allow insulins to be approved under abbreviated new drug applications as of 2020.
Number 3: The Congressional Budget Office and CMS report that the Lower Drug Costs Now Act would save on federal spending and improve health, at least in the short term.
Number 2: In a memorandum in support of its motion to dismiss an antitrust lawsuit, AbbVie said that the complaint could upend the balance between patent and antitrust laws and hurt innovation.
Number 1: Newly introduced bipartisan legislation would require HHS to evaluate Medicare Advantage plans based on whether biosimilars are available to enrollees.
Finally, last week, our e-newsletter asked whether you think that the UK Labour party’s proposal to use compulsory licensing in order to let the government develop cheaper generics is warranted.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
